Every 8-K that Aktis Oncology, Inc. (AKTS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow AKTS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AKTS filings page.
Aktis Oncology, Inc. reported second quarter 2026 results and outlined progress across its targeted radiopharmaceutical pipeline. The company highlighted first-in-human imaging and dosimetry data for AKY-2519 showing robust tumor uptake and limited normal tissue exposure, and continued enrollment in a Phase 1b trial of AKY-1189 in urothelial and other Nectin-4 expressing tumors. Aktis initiated a Phase 1b trial of AKY-2519 in metastatic castration-resistant prostate cancer and cleared regulatory review for a Phase 1b basket trial in other B7-H3 expressing tumors, both expected to yield preliminary data in 2027. An in-house GMP facility is expected to be operational in the second half of 2026 to support clinical supply. Cash, cash equivalents, and marketable securities were $517.3 million as of June 30, 2026, expected to fund operations into 2029. For the quarter, collaboration revenue was $3.4 million, research and development expenses $25.3 million, general and administrative expenses $7.0 million, and net loss $24.1 million.
Aktis Oncology reported first quarter 2026 results alongside significant clinical and financing progress. Cash, cash equivalents and marketable securities were $538.5 million as of March 31, 2026, up from $226.8 million at year-end, helped by a January IPO of 20,297,500 shares at $18.00 per share for gross proceeds of about $365.4 million. The company expects this cash to fund operations into 2029.
Collaboration revenue rose to $3.2 million from $1.4 million, while research and development expenses increased to $20.0 million and general and administrative expenses to $5.9 million, leading to a net loss of $18.3 million versus $15.0 million a year earlier. Aktis highlighted Fast Track–designated AKY-1189 and B7-H3–targeting AKY-2519, with multiple Phase 1b trials underway or planned and initial data readouts expected in 2027.
Aktis Oncology appointed Glenn Gormley, MD, PhD, age 72, as an independent Class I director, effective April 15, 2026, with a term running until the 2027 annual stockholder meeting. He will also serve as Co-Chairperson of the newly created Science and Technology Committee.
Under the company’s Non-Employee Director Compensation Policy, Dr. Gormley will receive annual cash fees of $45,000 for Board service and $15,000 for his committee co-chair role, both prorated. He was granted an option to purchase 37,866 shares of common stock under the 2026 Equity Incentive Plan, vesting in equal annual installments over three years, subject to continued service.
The filing also notes that current directors Helen S. Kim and Oleg Nodelman have decided to resign from the Board and all committees, effective May 20, 2026, and that their decisions were not due to any disagreement with the company’s operations, policies, or practices.
Aktis Oncology reported 2025 results and highlighted major R&D and financing milestones. The FDA cleared Investigational New Drug applications for AKY-2519, enabling a Phase 1b trial in mid-2026, while lead program AKY-1189 continues enrolling in a Phase 1b study and received Fast Track designation in February 2026.
Cash, cash equivalents and marketable securities were $226.8 million as of December 31, 2025, with a pro forma as adjusted cash position of $562.1 million after the January 2026 IPO, which the company believes will fund operations into 2029. 2025 collaboration revenue was $6.5 million, R&D expenses were $67.5 million, G&A expenses were $13.7 million, and net loss was $63.7 million, all higher than 2024 as the pipeline and organization expanded.
Aktis Oncology, Inc. adopted an amended and restated certificate of incorporation and bylaws in connection with the completion of its initial public offering on January 12, 2026. The new charter authorizes 480,000,000 shares of common stock, 10,000,000 shares of Class A common stock, and 10,000,000 shares of undesignated preferred stock that the board may issue in one or more series. It also eliminates prior preferred stock series, requires at least a two-thirds stockholder vote to remove a director for cause, creates a classified board with directors serving staggered three-year terms, and removes stockholder action by written consent.
The amended and restated bylaws, effective immediately prior to the IPO, establish detailed procedures for stockholder proposals and director nominations, revise indemnification provisions for directors and officers, and align the bylaws with the new charter terms.